

## 資料・統計

## 2022年発表論文一覧

## The List of Publications in 2022

【注記】複数発表者の表記について

1. 発表の記載通り、先頭から5名までを表記
2. 院外者名だけで5名になる場合は、et al（当院発表者名）、ほか（当院発表者名）と明記
3. グループ名があれば明記

## 内科（呼吸器）

No.	著者名	論題名	掲載誌名 巻(号)：始p～終p. 年	別刷 有*
1	Shiraishi Yoshimasa, Hakozaki Taiki, Nomura Shogo, Kataoka Tomoko, Tanaka Kentaro, et al. (Miura Satoru) (JCOG)	A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study)	Clinical Lung Cancer 23(4):e285-e288. 2022	
2	Hayashi Hidetoshi, Sugawara Shunichi, Fukuda Yasushi, Fujimoto Daichi, Miura Satoru, et al. (WJOG)	A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L).	Clinical Cancer Research 28(5):893-902. 2022	
3	Popat Sanjay, Hsia Te-Chun, Hung Jen-Yu, Jung Hyun Ae, Shih Jin-Yuan, et al. (Miura Satoru)	Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwi nG).	Oncologist 27(4):255-265. 2022	
4	Koyama Kenichi, Miura Satoru, Watanabe Satoshi, Shoji Satoshi, Koshio Jun, et al (NLCTG)	Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC.	Scientific Reports 12(1):6367. 2022	
5	Yang James Chih-Hsin, Schuler Martin, Popat Sanjay, Miura Satoru, Park Keunchil, et al	Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report.	Frontiers in Oncology 12:834704. 2022	
6	Kenmotsu Hirotsugu, Wakuda Kazushige, Mori Keita, Kato Terufumi, Sugawara Shunichi, et al. (Miura Satoru) (WJOG)	Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study.	Journal of Thoracic Oncology 17(9):1098-1108. 2022	

No.	著者名	論題名	掲載誌名 巻(号):始p~終p.年	別刷 有*
7	Akamatsu Hiroaki, Teraoka Shunsuke, Takamori Shinkichi, Miura Satoru, Hayashi Hidetoshi, et al (WJOG)	Nivolumab retreatment in non-small cell lung cancer patients who responded to prior immune-checkpoint inhibitors and had ICI-free intervals (WJOG9616L).	Clinical Cancer Research 28(15):OF1-OF7. 2022	
8	Miura Satoru, Jung Hyun Ae, Lee Shin Yup, Lee Seung Hyeun, Lee Min Ki, et al.	Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional Studies.	OncoTargets and therapy 15:873-882. 2022	
9	Ikeda Satoshi, Naito Tateaki, Miura Satoru, Ito Kentaro, Furuya Naoki, et al.	Pharmacotherapy for Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene Alterations: Could Immune Checkpoint Inhibitors Be a Game Changer?	Cancers (Basal) 14(19):4861. 2022	
10	Taniguchi Yuri, Shimokawa Tsuneo, Takiguchi Yuichi, Misumi Toshihiro, Nakamura Yukiko, et al. (Miura Satoru) (TORG)	A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630.	Clinical Cancer Research 28(20):4402-4409. 2022	
11	Ichikawa Kosuke, Watanabe Satoshi, Miura Satoru, Ohtsubo Aya, Shoji Satoshi, et al.	Prognostic significance of procalcitonin in small cell lung cancer.	Translational Lung Cancer Research 11(1):43-52. 2022	
12	田中 奨, 三浦 理	進展型小細胞肺癌	日本臨床 80(増刊8):540-545. 2022	
13	Seto Takashi, Nosaki Kaname, Shimokawa Mototsugu, Toyozaawa Ryo, Sugawara Shunichi, et al (Tanaka Hiroshi) (WJOG)	Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)	Journal for Immunotherapy of Cancer 10(2):e004025. 2022	
14	Shoji Satoshi, Miura Satoru, Watanabe Satoshi, Ohtsubo Aya, Nozaki Koichiro, et al. (NLCTG)	Phase II study of nanoparticle albumin-bound paclitaxel monotherapy for relapsed non-small cell lung cancer with patient-reported outcomes (NLCTG1302)	Translational Lung Cancer Research 11(7):1359-1368. 2022	
15	Watanabe Satoshi, Sakai Kazuko, Matsumoto Naoya, Koshio Jun, Ishida Akira, et al. (Kajiwara Tomosue, Koyama Kenichi, Miura Satoru)	Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501).	Cancers (Basel) 15(1):204. 2022	
16	Qiu Guihuan, Li Suyang, Li Bingliang, Yang Qingqing, Deng Haiyi, et al. (Miura Satoru)	Immune thrombocytopenia in a small cell lung cancer patient treated with atezolizumab: a case report.	Translational Lung Cancer Research 11(11):2346-2355. 2022	

No.	著者名	論題名	掲載誌名 巻(号)：始p～終p. 年	別刷 有*
17	Yoneshima Yasuto, Morita Satoshi, Ando Masahiko, Nakamura Atsushi, Iwasawa Shunichiro, et al. (Miura Satoru)	Nab-Paclitaxel for Previously Treated Advanced Non-Small Cell Lung Cancer: Analysis of Safety and Efficacy for Patients With Renal Impairment.	Clinical Lung Cancer 23(7):585-592. 2022	
18	Kenmotsu Hirotsugu, Wakuda Kazushige, Mori Keita, Kato Terufumi, Sugawara Shunichi, et al. (Miura Satoru) (WJOG)	Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study	Journal of Thoracic Oncology 17(9):1098-1108. 2022	
19	Fujimoto Daichi, Akamatsu Hiroaki, Morimoto Takeshi, Wakuda Kazushige, Sato Yuki, et al. (Miura Satoru)	Histologic transformation of epidermal growth factor receptor-mutated lung cancer.	European Journal of Cancer 166:41-50. 2022	
20	Sakata Shinya, Otsubo Kohei, Yoshida Hisako, Ito Kentaro, Nakamura Atsushi, et al. (Miura Satoru) (WJOG)	Real-world data on NGS using the OncoPrint DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L.	Cancer science 113(1):221-228. 2022	
21	K J O'Byrne, K H Lee, S-W Kim, K Park, Nishio Makoto, et al. (Tanaka Hiroshi)	First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients	ESMO Open 7(1):100394. 2022	
22	田中洋史, 阿部咲子, 高野可赴, 三浦 理, 広瀬貴之, ほか	新潟県立がんセンター新潟病院における新型コロナウイルス感染症対策	県立がんセンター新潟病院医誌 60(2):72-79. 2022	
23	三浦 理	がん悪液質治療の現状とアナモレリン塩酸塩を用いた治療の実例	新薬と臨牀 71(4):425-432. 2022	

## 内科 (腫瘍循環器)

No.	著者名	論題名	掲載誌名 巻(号)：始p～終p. 年	別刷 有*
1	大倉裕二	今後の腫瘍循環器診療の展望 つながる・ひろがる・腫瘍循環器診療	Heart View 26(10):1014-1020.2022	
2	Sakai Ryohei, Fujiki Shinya, Kashimura Takeshi, Tsuchiya Hiroki, Takahashi Kazuyoshi, et al. (Okura Yuji)	Long-Term Outcomes in Patients with Not-Retrieval Inferior Vena Cava Filter Under Anticoagulation.	International Heart Journal 63(2):306-311.2022	
3	向井幹夫, 大倉裕二, 草場仁志, 志賀太郎	不安に感じる心毒性とは？—読者アンケートの結果から	ケアネット連載「見落とさない！がんの心毒性」第9回 [掲載2022-3-1] <a href="https://www.carenet.com/series/oncocardio/cg002995_index.html">https://www.carenet.com/series/oncocardio/cg002995_index.html</a>	
4	大倉裕二	この心電図, QT延長ですか？ 休薬すべきですか？	ケアネット連載「見落とさない！がんの心毒性」第13回 [掲載2022-7-15] <a href="https://www.carenet.com/series/oncocardio/cg002995_index.html">https://www.carenet.com/series/oncocardio/cg002995_index.html</a>	

## 内科 (消化器)

No.	著者名	論題名	掲載誌名 巻(号):始p~終p. 年	別刷 有*
1	小林正明, 高橋祥史, 渡邊 玄	上皮性・腫瘍性陥凹病変 早期胃癌 (0-IIc,除菌後分化型腺癌)	消化器内視鏡 34(増刊):220-221. 2022	
2	小林正明, 北條雄暉, 丹羽佑輔, 高橋祥史, 今井径卓, ほか	分化型胃癌における <i>H.pylori</i> 感染と <i>H.pylori</i> 除菌後の違い	Helicobacter Research 26(1):13-17. 2022	
3	小林正明	collagenous gastritis	胃と腸 57(5):612. 2022	
4	小林正明, 北條雄暉, 丹羽佑輔, 高橋祥史, 今井径卓, ほか	<i>H.pylori</i> 除菌後胃癌 除菌後浸潤胃癌	消化器内視鏡 34(2):190-196. 2022	
5	小林正明	<i>H. pylori</i> 除菌後胃癌の内視鏡診断	消化器疾患最新の治療2023-2024, 山本博徳, 瀬戸泰之, 吉治仁志編 p19-22. 東京. 南江堂. 2022	
6	堀 亜洲, 小林正明, 富吉 圭, 丹羽佑輔, 高橋祥史, ほか	炎症性ポリープとの鑑別が必要であった食道胃接合部腺癌の1例	ENDOSCOPIC FORUM for digestive disease 38(2):111-117. 2022	
7	小林正明, 北條雄暉, 丹羽佑輔, 高橋祥史, 今井径卓, ほか	除菌後発見胃癌の内視鏡診断, 狭帯域光拡大観察の見地から, 表面微細構造に焦点を当てて	胃と腸 57(1):40-51. 2022	
8	Sato Chihiro, Takahashi Kazuya, Sato Hiroki, Naruse Takumi, Nakajima Nao, et al. (Kobayashi Masaaki)	Endoscopic Findings and Treatment of Gastric Neoplasms in Familial Adenomatous Polyposis.	Journal of Gastric Cancer 22(4):381-394. 2022	
9	Hashimoto Satoru, Sato Hiroki, Mizuno Ken-Ichi, Takahashi Kazuya, Takatsuna Masafumi, et al. (Kobayashi Masaaki)	Endoscopic Submucosal Dissection for Gastric Tube Carcinoma after Esophagectomy Contributes to Long-Term Outcomes.	Canadian Journal of Gastroenterology & Hepatology 2022 Feb 10; 2022:1631415. doi: 10.1155/2022/1631415.eCollection 2022.	
10	Kitano Masayuki, Yoshida Makoto, Ashida Reiko, Kita Emiri, Katanuma Akio, et al. (Shioji Kazuhiko)	Needle tract seeding after endoscopic ultrasound-guided tissue acquisition of pancreatic tumors: Nationwide survey in Japan	Digestive Endoscopy 34(7):1442-1455. 2022	*
11	塩路和彦, 北條雄暉, 丹羽佑輔, 高橋祥史, 今井径卓, ほか	当院における超音波内視鏡下穿刺吸引法 (EUS-FNA) の現状	県立がんセンター新潟病院医誌 60(2):55-60. 2022	*
12	Yoshida Yukio, Kobayashi Satochi, Ueno Makoto, Morizane Chigusa, Tsuji Kunihiro, et al. (Shioji Kazuhiko)	Efficacy of chemotherapy for patients with metastatic or recurrent pancreatic adenosquamous carcinoma: A multicenter retrospective analysis	Pancreatology 22(8):1159-1166. 2022	*
13	Todaka Akiko, Nara Satoshi, Motoi Fuyuhiko, Morinaga Soichiro, Toshiyama Reishi, et al. (Shioji Kazuhiko)	Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study	Anticancer Research 42(2):893-902. 2022	*

No.	著者名	論題名	掲載誌名 巻(号):始p~終p. 年	別刷有*
14	Kobayashi Satoshi, Suzuki Motoko, Ueno Makoto, Maruki Yuta, Okano Naohiro, et al. (Shioji Kazuhiko)	Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer	The Oncologist 27(10):e774-e782. 2022	*

## 内科 (糖尿病)

No.	著者名	論題名	掲載誌名 巻(号):始p~終p. 年	別刷有*
1	谷 長行	【今だから知りたい糖尿病患者のがん 病態・治療・支援】 ケースで考えよう 糖尿病とがんを併せもつ患者の療養支援 がん化学療法によるステロイド投与で血糖コントロールが悪化し、インスリン導入となった患者	糖尿病ケア+ 19(6):820-823. 2022	

## 消化器外科

No.	著者名	論題名	掲載誌名 巻(号):始p~終p. 年	別刷有*
1	Takahashi Yoshikazu, Sunakawa Yu, Inoue Eisuke, Kawabata Ryohei, Ishiguro Atsushi, et al. (Yabusaki Hiroshi)	Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08)	Gastric Cancer 25(1):235-244. 2022	
2	Mine Shinji, Kurokawa Yukinori, Takeuchi Hiroya, Terashima Masanori, Yasuda Takushi, et al. (Yabusaki Hiroshi)	Postoperative complications after a transthoracic esophagectomy or a transhiatal gastrectomy in patients with esopagogastric junctional cancers: a prospective nationwide multicenter study.	Gastric Cancer 25(2):430-437. 2022	
3	Chin Keisho, Takahari Daisuke, Kawabata Ryohei, Hosaka Hisashi, Saitou So, et al. (Yabusaki Hiroshi)	Initial Safety Analysis of CapeOx for Elderly Patients With Advanced Gastric Cancer Patients: A Phase II Trial.	Anticancer Research 42(5):2683-2687. 2022	
4	Kano Yosuke, Ichikawa Hiroshi, Hanyu Takaaki, Muneoka Yusuke, Ishikawa Takashi, et al. (Aizawa Masaki, Matsuki Atsushi, Yabusaki Hiroshi, Bamba Takeo, Nakagawa Satoru)	Conversion surgery for stage IV gastric cancer: a multicenter retrospective study.	BMC Surgery 22(1):428. 2022	
5	Aizawa Masaki, Yabusaki Hiroshi, Matsuki Atsushi, Bamba Takeo, Nakagawa Satoru	Intracorporeal hand-sewn anastomosis following pylorus-preserving gastrectomy: surgical technique and short-term surgical outcome	Langenbeck's Archives of Surgery 407(4):1711-1720. 2022	
6	Aizawa Masaki, Yabusaki Hirsoshi, Nakada Koji, Matsuki Atsushi, Bamba Takeo, et al. (Nakagawa Satoru)	Simple modifications of conventional esophagogastric anastomosis after proximal gastrectomy adequately reduces the postoperative reflux esophagitis: a retrospective analysis of posterolateral fundoplication	Langenbeck's Archives of Surgery 407(7):3153-3160. 2022	

No.	著者名	論題名	掲載誌名 巻(号):始p~終p.年	別刷 有*
7	Kumagai Koshi, Lee Sang-Woong, Ohira Masaichi, Aizawa Masaki, Kamiya Satoshi et al	Time interval after various types of gastrectomy until metachronous multiple gastric cancer: Analysis of data from a nationwide Japanese survey	Molecular and Clinical Oncology 16(2):54. 2022	
8	會澤雅樹, 藪崎 裕, 番場竹生, 松木 淳, 酒井 剛, ほか	逆流防止処置と空腸流出路の半閉鎖を付加した腹腔鏡下噴門側胃切除後のダブルトラクト再建	手術 76(11):1743-1750. 2022	
9	Mitani Seiichiro, Kato Ken, Daiko Hiroyuki, Ito Yoshinori, Nozaki Isao, et al. (Nakagawa Satoru)	Second primary malignancies in patients with clinical T1bN0 esophageal squamous cell carcinoma after definitive therapies: supplementary analysis of the JCOG trial: JCOG0502	Journal of Gastroenterology 57(7):455-463. 2022	
10	Nozaki Isao, Machida Ryunosuke, Kato Ken, Daiko Hiroyuki, Ito Yoshinori, et al. (Nakagawa Satoru)	Long-term survival of patients with T1bN0M0 esophageal cancer after thoracoscopic esophagectomy using data from JCOG0502: a prospective multicenter trial.	Surgical Endoscopy 36(6):4275-4282. 2022	
11	Oshima Kotoe, Kato Ken, Ito Yoshinori, Daiko Hiroyuki, Nozaki Isao, et al. (Nakagawa Satoru)	Prognostic biomarker study in patients with clinical stage I esophageal squamous cell carcinoma: JCOG0502-A1	Cancer Science 113(3):1018-1027. 2022	
12	Shimajima Yukio, Nomura Tatsuya, Takano Kabuto, Nakayasu Yasuyo, Kono Teppei, et al.	A case of pathological complete response after neoadjuvant therapy for resectable pancreatic cancer	Gan To Kagaku Ryoho 49(13):1662-1664. 2022	
13	Kataoka Kozo, Fujita Shin, Inomata Masafumi, Takii Yasumasa, Ohue Masayuki, et al.	Challenges needed to be overcome in multi-institutional surgical trials: accumulated experience in the JCOG Colorectal Cancer Study Group (CCSG).	Japanese Journal of Clinical Oncology 52(2):103-107. 2022	*
14	Takeyama Hiroshi, Murata Kohei, Takeda Takashi, Fujii Makoto, Kagawa Yoshinori, et al, (Takii Yasumasa). study group of appendiceal neoplasms in Japan Society of Colorectal Cancer Research Group	Clinical Significance of Lymph Node Dissection and Lymph Node Metastasis in Primary Appendiceal Tumor Patients After Curative Resection: a Retrospective Multicenter Cohort Study.	Journal of Gastrointestinal Surgery 26(1):128-140. 2022	*
15	Manabe Takahiro, Takii Yasumasa, Oyanagi Hidehito, Nogami Hitoshi, Maruyama Satoshi.	Is the ileocolic artery crossing pattern related to oncological outcomes of right sided colon cancer?	Surgical Endoscopy 36(10):7210-7218. 2022	*
16	Sato Harunobu, Maeda Kotaro, Kinugasa Yusuke, Kagawa Hiroyasu, Tsukamoto Shunsuke, et al. (Takii Yasumasa)	Management of inguinal lymph node metastases from rectal and anal canal adenocarcinoma.	Colorectal Disease 24(10):1150-1163. 2022	*

No.	著者名	論題名	掲載誌名 巻(号):始p~終p. 年	別刷 有*
17	Takii Yasumasa, Mizusawa Junki, Kanemitsu Yukihide, Komori Koji, Shiozawa Manabu, et al.	The Conventional Technique Versus the No-touch Isolation Technique for Primary Tumor Resection in Patients With Colon Cancer (JCOG1006).A Multi-center, Open-label, Randomized, Phase III Trial	Annals of Surgery 275(5):849-855. 2022	*
18	Ito Takahiko, Takashima Atsuo, Yamazaki Kentaro, Yukami Hiroki, Uetake Hiroyuki, et al. (Takii Yasumasa)	Primary tumor location as a predictor of survival in patients with RAS wild type colorectal cancer who receive molecularly targeted drugs as first line therapy: a multicenter real world observational study by the Japanese Society for Cancer of the Colon and Rectum.	International Journal of Clinical Oncology 27(9):1450-1458. 2022	*
19	Shimada Yoshihumi, Nakano Mae, Mizuno Ken-ichi, Yokoyama Junji, Matsumoto Akio, et al. (Takii Yasumasa)	Gene panel testing detects important genetic alterations in ulcerative colitis-associated colorectal neoplasia	Oncology Letters 24(6):442. 2022	*
20	Nakano Mae, Shimada Yoshifumi, Matsumoto Yoshifumi, Saiki Takuro, Zhou Qiliang, et al. (Takii Yasumasa)	Efficacy of BRAF inhibitor and anti-EGFR antibody in colorectal neuroendocrine carcinoma	Clinical Journal of Gastroenterology 15(2):413-418. 2022	*
21	瀧井康公, 丸山 聡, 野上 仁	誌上ディベート(第32回)大腸癌肝転移に対する根治的切除後症例に対して補助化学療法を行うか行うvs.行わない行わない立場から	消化器外科 45(6):701-705. 2022	
22	丸山 聡, 瀧井康公, 野上 仁	本邦の大腸癌治療の現状と展望—海外における標準治療と比較して結腸癌の術前化学療法—その適応と功罪	日本外科学会雑誌 123(3):234-239. 2022	

## 呼吸器外科

No.	著者名	論題名	掲載誌名 巻(号):始p~終p. 年	別刷 有*
1	Saji Hisashi, Okada Morihito, Tsuboi Masahiro, Nakajima Ryu, Suzuki Kenji, et al. (Aoki Tadashi) West Japan Oncology Group and Japan Clinical Oncology Group	Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial	Lancet 399(10335):1607-1617. 2022	
2	Takahashi Toshiaki, Sakai Kazuko, Kenmotsu Hirotsugu, Yoh Kiyotaka, Daga Haruko, Ohira Tatsuo, et al. (Aoki Tadashi)	Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy	Cancer Science 113(1):287-296. 2022	

## 骨軟部腫瘍・整形外科

No.	著者名	論題名	掲載誌名 巻(号):始p~終p. 年	別刷 有*
1	畠野宏史, 山岸哲郎, 柳橋和仁	がんの転移性軟部腫瘍に対して切除術を行った症例の検討	日本臨床整形外科学会雑誌 47(1):109-110. 2022	
2	宮崎友宏, 畠野宏史, 山岸哲郎, 柳橋和仁, 有泉高志	失調症状の出現から診断された脳髄黄色腫症の1例	整形外科 73(1):41-45. 2022	

No.	著者名	論題名	掲載誌名 巻(号):始p~終p. 年	別刷 有*
3	Tanaka Kazuhiro, Machida Ryunosuke, Kawai Akira, Nakayama Robert, Tsukushi Satoshi, et al. (Hatano Hiroshi)	Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306.	British Journal of Cancer 127(8):1487-1496. 2022	
4	Urakawa Hiroshi, Nagano Akihito, Machida Ryunosuke, Tanaka Kazuhiro, Kataoka Tomoko, et al. (Hatano Hiroshi)	A randomized phase III trial of denosumab before curettage for giant cell tumor of bone. JCOG1610	Japanese Journal of Clinical Oncology 52(9):1021-1028. 2022	
5	山岸哲郎, 畠野宏史	境界悪性(中間群)の軟部腫瘍に対する治療戦略	整形・災害外科 65(3):271-278. 2022	

## 皮膚科

No.	著者名	論題名	掲載誌名 巻(号):始p~終p. 年	別刷 有*
1	竹之内辰也	基底細胞癌	今日の皮膚疾患治療指針第5版. 佐藤伸一, 藤本学, 門野岳史, 椛島健治編 p770-772. 東京. 医学書院. 2022	
2	松井 悠, 佐々木仁, 高塚純子, 竹之内辰也	臍部に生じた子宮内膜症の2例 既報告例の統計学的解析を含めて	臨床皮膚科 76(2):141-146. 2022	
3	松井 悠, 竹之内辰也	【最近のトピックス2022】皮膚疾患治療のポイント 小児爪色素線条60例の自然経過 Wait & seeでよいのか?	臨床皮膚科 76(5):104-108. 2022	
4	山崎直也, 爲政大幾, 宇原 久, 清原祥夫, 竹之内辰也, ほか	悪性黒色腫(メラノーマ)薬物療法の手引き version1.2022	Skin Cancer 37(2):67-71. 2022	
5	Kikuchi Katsuko, Yamazaki Naoya, Nozawa Keiko, Fukuda Haruhiko, Shibata Taro, et al. (Takatsuka Sumiko, Takenouchi Tatsuya)	Topical corticosteroid therapy for facial acneiform eruption due to EGFR inhibitors in metastatic colorectal cancer patients: a randomized controlled trial comparing starting with a very strong or a weak topical corticosteroid (FAEISS study, NCCH1512, colorectal part)	Supportive Care in Cancer 30(5):4497-4504. 2022	
6	Kato Junji, Namikawa Kenjiro, Uehara Jiro, Nomura Motoo, Nakamura Yasuhiro, et al. (Takenouchi Tatsuya)	Prognoses of patients with melanoma who continue/discontinue anti-programmed death-1 therapy after achieving a complete response in a real-world setting: a multicentre retrospective study	British Journal of Dermatology 187(4):594-596. 2022	
7	Kamimura Anna, Nakamura Yasuhiro, Takenouchi Tatsuya, Matsushita Sigeto, Omodaka Toshikazu, et al.	Concordance in judgment of clinical borders of basal cell carcinomas in Japanese patients: A preliminary study of JCOG2005 (J-BASE-MARGIN)	Journal of Dermatology 49(9):837-844. 2022	
8	Yamazaki Naoya, Isei Taiki, Kiyohara Yoshio, Koga Hiroshi, Kojima Takashi, et al. (Takenouchi Tatsuya)	A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma	Cancer Science 113(8):2798-2806. 2022	



No.	著者名	論題名	掲載誌名 巻(号):始p~終p. 年	別刷 有*
9	Nakamura Yasuhiro, Namikawa Kenjiro, Kiniwa Yukiko, Kato Hiroshi, Yamasaki Osamu, et al. (Takenouchi Tatsuya)	Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients	European Journal of Cancer 176:78-87. 2022	
10	Yoto Ayumi, Shimada Kanade, Takatsuka Sumiko, Takenouchi Tatsuya.	Systemic melanoma therapy at the end of life: A single institutional retrospective study in Japan	JAAD International 10:51-52. 2022	
11	Ohshima Shusuke, Ueki Yushi, Yokoyama Yusuke, Takahashi Takeshi, Shodo Ryusuke, et al. (Takatsuka Sumiko, Takenouchi Tatsuya)	Treatment outcomes of mucosal melanoma of head and neck: Efficacy of immune checkpoint inhibitors for advanced disease	Frontiers in Surgery 9:1032626. 2022	

## 泌尿器科

No.	著者名	論題名	掲載誌名 巻(号):始p~終p. 年	別刷 有*
1	Kato Takuma, Hirama Hiromi, Mitsuzuka Koji, Maruyama Satoru, Sasaki Hiroshi, et al. (Saito Toshihiro)	Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN.	Prostate Cancer and Prostatic Diseases 25(4):666-671. 2022	
2	Tohi Yoichiro, Kato Takuma, Nakamura Masaki, Matsumoto Ryuji, Sasaki Hiroshi, et al. (Saito Toshihiro)	Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study.	International Journal of Clinical Oncology 27(1):194-201. 2022	
3	Tohi Yoichiro, Kato Takuma, Yokomizo Akira, Mitsuzuka Koji, Tomida Ryotaro, et al. (Saito Toshihiro, Tanikawa Toshiki)	Impact of health-related quality of life on repeat protocol biopsy compliance on active surveillance for favorable prostate cancer: results from a prospective cohort in the PRIAS-JAPAN study	Urologic Oncology 40(2):56.e9-56.e15. 2022	
4	Nagumo Yoshiyuki, Onozawa Mizuki, Kojima Takahiro, Terada Naoki, Shiota Masaki, et al. (Saito Toshihiro)	Efficacy of combined androgen blockade therapy in patients with metastatic hormone-sensitive prostate cancer stratified by tumor burden	International Journal of Urology 29(5):398-405. 2022	
5	Shiota Masaki, Takamatsu Dai, Kimura Takahiro, Tashiro Kojiro, Matsui Yoshiyuki, et al. (Saito Toshihiro)	Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node-positive prostate cancer	Cancer science 113(7):2386-2396. 2022	
6	Tohi Yoichiro, Kato Takuma, Miyakawa Jimpei, Matsumoto Ryuji, Sasaki Hiroshi, et al. (Saito Toshihiro)	Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS-JAPAN study	Japanese Journal of Clinical Oncology 52(9):1056-1061. 2022	

## 婦人科

No.	著者名	論題名	掲載誌名 巻(号):始p~終p. 年	別刷 有*
1	Egawa-Takata Tomomi, Ueda Yutaka, Ito Kimihiko, Hori Kensuke, Tadahiro Shoji, et al. (Kikuchi Akira)	Adjuvant Chemotherapy for Endometrial Cancer (ACE) trial: A randomized phase II study for advanced endometrial carcinoma	Cancer Science 113(5):1693-1701. 2022	
2	Yoshida Hiroshi, Kikuchi Akira, Tsuda Hitoshi, Sakamoto Atsuhiko, Fukunaga Masaharu	Discrepancies in pathological diagnosis of endometrial stromal sarcoma: a multi-institutional retrospective study from the Japanese clinical oncology group	Human Pathology 124:24-35. 2022	

## 頭頸部外科

No.	著者名	論題名	掲載誌名 巻(号):始p~終p. 年	別刷 有*
1	鎌田悠志, 富樫孝文, 西條幸平, 佐藤雄一郎, 堀井 新	家族性大腸腺腫症を合併した甲状腺篩型乳頭癌: 術前診断の重要性について	日本耳鼻咽喉科頭頸部外科学会 会報 125(6):1008-1013. 2022	*
2	Saigusa Natsuki, Hirai Hideaki, Tada Yuichiro, Kawakita Daisuke, Nakaguro Masato, et al. (Togashi Takafumi)	The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy	Frontiers in Oncology 11:779882. 2022	*
3	Kohsaka Shinji, Tada Yuichiro, Ando Mizuo, Nakaguro Masato, Shirai Yukina, et al. (Togashi Takafumi)	Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling.	NPJ Precision Oncology 6(1):82. 2022	*
4	Kawakita Daisuke, Nagao Toshitaka, Takahashi Hideaki, Kano Satoshi, Honma Yoshitaka, et al. (Togashi Takafumi)	Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma.	Therapeutic Advances in Medical Oncology 14:17588359221119538. 2022	*
5	Otaki Kohei, Takahashi Takeshi, Tanaka Ryoko, Saijo Kohei, Omata Jo, et al. (Ota Hisayuki, Togashi Takafumi)	Chemoradiotherapy with 3-weekly CDDP 80 mg/m <sup>2</sup> for head and neck squamous cell carcinoma: 5-year survival data from a phase 2 study	Frontiers in Surgery 9:1035349. 2022	*
6	Ohshima Shusuke, Ueki Yushi, Yokoyama Yusuke, Takahashi Takeshi, Shodo Ryusuke, et al. (Togashi Takafumi)	Treatment outcomes of mucosal melanoma of head and neck: Efficacy of immune checkpoint inhibitors for advanced disease	Frontiers in Surgery 9:1032626. 2022	*

## 放射線診断科

No.	著者名	論題名	掲載誌名 巻(号):始p~終p. 年	別刷 有*
1	関 裕史	令和元年度胃がん検診成績	新潟市医師会報 610:41-46. 2022	

No.	著者名	論題名	掲載誌名 巻(号):始p~終p. 年	別刷 有*
2	Ikeda Masafumi, Arai Yasuaki, Inaba Yoshitaka, Tanaka Toshihiro, Sugawara Shunsuke, et al. (Seki Hiroshi) Japan Interventional Radiology in Oncology Study Group	Conventional or Drug-Eluting Beads? Randomized Controlled Study of Chemoembolization for Hepa- tocellular Carcinoma: JIVROSG-1302	Liver Cancer 11(5):440-450. 2022	
3	古泉直也	この病変から考えられる疾患は? [胸部画像 診断トレーニング (40)]	日本医事新報 5097:7-8. 2022	
4	布澤悠磨, 麻谷美奈, 石川浩史	画像でみかける偶発的所見のマネジメント 2022-あなたならどう書く? 子宮頸部の囊 胞性病変	画像診断 42(11):A136-138. 2022	
5	布澤悠磨, 麻谷美奈, 石川浩史	画像でみかける偶発的所見のマネジメント 2022-あなたならどう書く? チョコレート 嚢胞とその他の血性嚢胞性病変	画像診断 42(11):A144-146. 2022	

## 放射線治療科

No.	著者名	論題名	掲載誌名 巻(号):始p~終p. 年	別刷 有*
1	Matsumoto Yasuo	A pictorial essay on radiological changes after ste- reotactic body radiation therapy for lung tumors.	Japanese Journal of Radiology 40(7):647-663. 2022	
2	Nozaki Miwako, Kagami Yoshikazu, Takahashi Mitsuhiro, Machida Ryunosuke, Sekino Yuta, et al. (Matsumoto Yasuo)	Evaluation of breast cosmetic changes with a com- puter-software; the breast cancer conservative treat- ment cosmetic results (BCCT. core) in hypofraction- ated whole breast irradiation after breast-conserving surgery-supplementary analysis of multicenter single- arm confirmatory trial: JCOG0906.	Breast Cancer 29(6):1042-1049. 2022	
3	Nakano Toshimichi, Aoyama Hidefumi, Onodera Shunsuke, Igaki Hiroshi, Matsumoto Yasuo, et al. (Kanemoto Ayaie) Japanese Radiation Oncology Study Group 13-1 (JROSG13-1) Investigators	Reduced-dose WBRT combined with SRS for 1-4 brain metastases aiming at minimizing neurocogni- tive function deterioration without compromising brain tumor control.	Clinical and Translational Radiation Oncology 37:116-129. 2022	
4	Kanemoto Ayaie, Sugita Tadashi, Ayukawa Fumio, Takahashi Kotaro, Horiuchi Ayano, et al.	Clinical results of image-guided interstitial brachyther- apy with or without external beam radiotherapy for postsurgical vaginal recurrence of cervical and en- dometrial cancers.	Japanese Journal of Radiology 40(6):639-644. 2022	
5	Ikushima Hitoshi, Haga Akihiro, Ando Ken, Kato Shingo, Kaneyasu Yuko, et al. (Kanemoto Ayaie) Japanese Radiation Oncology Study Group	Prediction of out-of-field recurrence after chemora- diotherapy for cervical cancer using a combination model of clinical parameters and magnetic reso- nance imaging radiomics: a multi-institutional study of the Japanese Radiation Oncology Study Group.	Journal of Radiation Research 63(1):98-106. 2022	
6	Murakami Naoya, Ando Ken, Murata Masumi, Murata Kazutoshi, Ohno Tatsuya, et al. (Kanemoto Ayaie)	An Asian multi-national multi-institutional retro- spective study comparing intracavitary versus the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical carcinoma.	Journal of Radiation Research 63(3):412-427. 2022	

No.	著者名	論題名	掲載誌名 巻(号):始p~終p.年	別刷 有*
7	Okonogi Noriyuki, Murakami Naoya, Ando Ken, Murata Masumi, Murata Kazutoshi, et al. (Kanemoto Aya)	An Asian multi-national, multi-institutional, retrospective study on image-guided brachytherapy in cervical adenocarcinoma and adenosquamous carcinoma.	Journal of Contemporary Brachytherapy 14(4):311-320. 2022	
8	松本康男, 鮎川文夫, 金本彩恵, 吉村奈津子, 杉田 公	2020年放射線治療の概要	県立がんセンター新潟病院医誌 60(2):124-127. 2022	

### 病理部

No.	著者名	論題名	掲載誌名 巻(号):始p~終p.年	別刷 有*
1	川崎 隆, ほか	研究部における新型コロナウイルス対策-PCR検査の構築-	県立がんセンター新潟病院医誌 60(2):80-89. 2022	
2	佐藤由美, 西村広栄, 桜井友子, 長尾 緑, 新保 基, ほか	2020年病理部/病理診断科業務統計	県立がんセンター新潟病院医誌 60(2):128-134. 2022	

### 臨床検査部

No.	著者名	論題名	掲載誌名 巻(号):始p~終p.年	別刷 有*
1	小方則夫	悪性疾患治療にともなうB型肝炎ウイルスならびにC型肝炎ウイルスの複製活性亢進への対策 国際的エビデンスに基づく診療フローチャート作成の提言 (免疫チェックポイントインヒビターを含めて)	県立がんセンター新潟病院医誌 60(2):61-71. 2022	

### 中央放射線部

No.	著者名	論題名	掲載誌名 巻(号):始p~終p.年	別刷 有*
1	Sasaki Yuki, Kondo Yohan, Aoki Tadashi, Koizumi Naoya, Ozaki Toshiro, et al. (Seki Hiroshi)	Use of deep learning to predict postoperative recurrence of lung adenocarcinoma from preoperative CT	International Journal of Computer Assisted Radiology and Surgery 17(9):1651-1661. 2022	
2	Yahara Yasuhito, Tamura Manami, Seki Shoji, Kondo Yohan, Makino Hiroto, et al.	A deep convolutional neural network to predict the curve progression of adolescent idiopathic scoliosis: a pilot study	BMC Musculoskeletal Disorders 23(1):610. 2022	
3	小林一恵	【新型コロナウイルス対策-2020年からの振り返りと今後】中央放射線部放射線診断科における新型コロナウイルス感染症の感染対策	県立がんセンター新潟病院医誌 60(2):90-95. 2022	

### 患者サポートセンター

No.	著者名	論題名	掲載誌名 巻(号):始p~終p.年	別刷 有*
1	中島志保	【新型コロナウイルス対策-2020年からの振り返りと今後】小児科病棟におけるオンライン保育について	県立がんセンター新潟病院医誌 60(2):106-109. 2022	

## 緩和ケアセンター

No.	著者名	論題名	掲載誌名 巻(号):始p～終p. 年	別刷 有*
1	長崎揚子	【伝えます!私の分野の看護で大切なこと】 (Theme 10) がん看護	Expert Nurse 38(4):86-91. 2022	
2	岡村利佳	【心疾患, 脂質異常症, 糖尿病, がん… 脳神経ナースに必須の脳以外の疾患の知識と観察点】 乳がん	Brain Nursing 38(5):703-707. 2022	

## 薬剤部

No.	著者名	論題名	掲載誌名 巻(号):始p～終p. 年	別刷 有*
1	吉野真樹	第2章 疾患別にみるハイリスク薬のフォローアップ 抗がん薬 免疫チェックポイント阻害薬 - 肺がんへの治療の副作用マネジメント	月刊薬事 64(10):2176-2188. 2022	
2	吉野真樹	第7章 がん薬物療法における薬剤師の役割 5 多職種チームの中での薬剤師の役割 5-5 免疫関連有害事象マネジメント (中小規模病院向け)	臨床腫瘍薬学 第2版 日本臨床腫瘍薬学会編集 pp917-923. 東京. じほう. 2022	
3	吉野真樹, 小山建一	第2章 実践! 3ステップで推論する副作用 Case16 この「筋力低下」は免疫チェックポイント阻害薬によるものですか?	「これ副作用?」と思ったときの3つの推論ステップ 副作用のみかた・考えかた②, 鈴木大, 鈴木信也, 今井徹, 山田和範編集 pp288-307. 東京. じほう. 2022	
4	Mitsuboshi Satoru, Niimura Takahiro, Yoshino Masaki, Sakamoto Yoshika, Zamami Yoshito, et al.	Fluoropyridimidine use and hypertriglyceridemia among Japanese patients: analysis of adverse event database.	International Journal of Clinical Pharmacy. 44(1):260-263. 2022.	*
5	牛腸明広, 吉野真樹, 樋口智恵, 佐々木奈穂, 田川千明, ほか	腎細胞がんに対するニボルマブ適用症例の甲状腺機能に先行治療のチロシンキナーゼ阻害薬投与後の甲状腺機能低下症が与える影響	日本病院薬剤師会雑誌 58(12):1427-1433. 2022	
6	吉野真樹, 大倉裕二	深掘りしてみよう! ベバシズマブ併用化学療法	ケアネット連載「見落とさない! がんの心毒性」第14回 [掲載2022-8-22] <a href="https://www.carenet.com/series/on-cocardio/cg002995_index.html">https://www.carenet.com/series/on-cocardio/cg002995_index.html</a>	

## 看護部

No.	著者名	論題名	掲載誌名 巻(号):始p～終p. 年	別刷 有*
1	青海直子	【心疾患, 脂質異常症, 糖尿病, がん… 脳神経ナースに必須の脳以外の疾患の知識と観察点】 肺がん	Brain Nursing 38(5):698-702. 2022	
2	武石礼子	【心疾患, 脂質異常症, 糖尿病, がん… 脳神経ナースに必須の脳以外の疾患の知識と観察点】 大腸がん (ストーマ含む)	Brain Nursing 38(5):708-713. 2022	
3	磯貝佐知子	えびでんす・あれんじ・な～しんぐ (EAN) 実践力を上げる工夫【第32回】免疫療法-副作用の早期発見・対応のための取り組み	緩和ケア 32(5):436-437. 2022	
4	鈴木なつき, 筒井真理子	【新型コロナウイルス対策-2020年からの振り返りと今後】 COVID-19の流行で生じた外来診療と救急外来の変化と取り組み	県立がんセンター新潟病院医誌 60(2):101-105. 2022	

## 医療安全管理室

No.	著者名	論題名	掲載誌名 巻(号):始p~終p.年	別刷 有*
1	小山和子	【新型コロナウイルス対策-2020年からの振り返りと今後】がんセンターの新型コロナウイルス感染症対策 感染管理認定看護師の苦悩	県立がんセンター新潟病院医誌 60(2):96-100.2022	

## 情報調査部

No.	著者名	論題名	掲載誌名 巻(号):始p~終p.年	別刷 有*
1	塩路和彦	2019年院内がん登録	県立がんセンター新潟病院医誌 60(2):135-138.2022	
2	高橋里緒	コロナ禍の患者図書サービス	ほすびたるらいぶらりあん 47(1):39-42.2022	

## 経営課

No.	著者名	論題名	掲載誌名 巻(号):始p~終p.年	別刷 有*
1	金子知則	【新型コロナウイルス対策-2020年からの振り返りと今後】新型コロナウイルス禍における経営環境について	県立がんセンター新潟病院医誌 60(2):110-115.2022	